

RIBER

Press release – 2010 first-half revenues

Bezons, July 15, 2010 - 5:45 PM

2010 first-half revenues: €4.4 million €16.9 million order book: +178%

Bezons, July 15, 2010 – 5:45 pm – RIBER, the global leader for molecular beam epitaxy (MBE), recorded €4.4 million in revenues over the first half of 2010, with €1.5 million for the second quarter. Not included in H1 revenues are two systems which have been produced and will be delivered during the second half of the year for a total of €4 million. With an order book representing €16.9 million, RIBER has excellent visibility over its business for the second half of the year.

€'000,000	H1 2010	H1 2009	Change
Systems	1.1	3.1	-64%
Services and accessories	2.7	1.7	+58%
Cells and sources	0.5	1.0	-51%
Total reported revenues*	4.4	5.9	-26%
Systems order book	13.4	4.6	+193%
Cells and accessories order book	3.5	1.5	+130%
Total order book	16.9	6.1	+178%

*Not including two systems which are currently being delivered with a total value of €4 million

First-half revenues not significant

During the first half of 2010, RIBER delivered two systems and finalized the production of two others, which, on account of the contractual timeframes, will be delivered during the second half of the year. At the end of June 2009, four systems had been delivered. In this context, machine sales came to €1.1 million at June 30, 2010, compared with €3.1 million at June 30, 2009.

Sales of evaporation sources and cells are down in relation to the first half of 2009 since this year's delivery schedule is concentrated over the second half of the year. The services and accessories business achieved record growth, up 58% compared with the first half of 2009.

At June 30, 2010, the breakdown of RIBER's sales was as follows: 51% in Europe, 20% in Asia and 30% in North America.

Favorable outlook for 2010

The order book represents a record level of €16.9 million, 178% higher than at June 30, 2009. It includes 10 MBE systems, with two production systems and eight research systems.

The order book also includes the largest effusion cell orders ever recorded by RIBER, reflecting its arrival in the strongly growing solar and OLED sectors.

The very strong growth achieved in the order book confirms the relevance of RIBER's business model and its strategic choices based on:

- Continuing to further strengthen RIBER's leadership on the market for molecular beam epitaxy machines;
- Capitalizing on the installed base and growing sales of epitaxy equipment, spare parts and accessories, as well as the corresponding services;
- Releasing a range of high value-added equipment and services on the market for strong-growth application fields (thin-layer solar cells, OLED lighting and screens, etc.).

In view of the current order book, revenues are expected to total around €19 million for 2010, enabling RIBER to confirm its target for profitability growth.

Next date: first-half earnings on September 7, 2010 (after close of trading).

About RIBER:

Riber designs and produces molecular beam epitaxy (MBE) systems as well as evaporation sources and cells for the semiconductor industry. This high-technology equipment is essential for the manufacturing of compound semiconductor materials and new materials that are used in numerous consumer applications, such as new information technologies, OLED flat screens and new generation solar cells.

Riber is listed on Euronext Paris Compartment "C" and is part of the CAC IT index.

ISIN: FR0000075954 Reuters code: RIBE.PA Bloomberg code: RIB: FP

Riber has been innovation certified by OSEO, the dedicated French innovation agency, enabling it to qualify for French innovation mutual funds (FCPI).

Your contacts:

RIBER

Olivier Handschumacher
tel: +33 1 39 96 65 00
ohandschumacher@riber.fr

CALYPTUS

Cyril Combe
tel: +33 1 53 65 68 68
cyril.combe@calyptus.net

www.riber.com